Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 27.85 -5.40% -1.59
AKCA closed down 5.4 percent on Friday, March 22, 2019, on 82 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical AKCA trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 200 DMA Bearish 0.00%
Mar 22 Fell Below 50 DMA Bearish 0.00%
Mar 22 180 Bearish Setup Bearish Swing Setup 0.00%
Mar 22 Expansion Pivot Sell Setup Bearish Swing Setup 0.00%
Mar 22 Outside Day Range Expansion 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 200 DMA Support Bullish -5.40%
Mar 21 Crossed Above 50 DMA Bullish -5.40%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.40%
Mar 21 NR7 Range Contraction -5.40%

Older signals for AKCA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Biopharmaceutical Medical Specialties Dyslipidemia Cardiology Low Density Lipoprotein Lipids Lipoproteins Antisense RNA Lipid Disorders Lipoprotein Lipase Deficiency Familial Chylomicronemia Syndrome Familial Partial Lipodystrophy
Is AKCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 40.75
52 Week Low 17.74
Average Volume 260,292
200-Day Moving Average 28.7256
50-Day Moving Average 28.978
20-Day Moving Average 30.579
10-Day Moving Average 29.579
Average True Range 1.7316
ADX 18.02
+DI 16.7018
-DI 20.4693
Chandelier Exit (Long, 3 ATRs ) 30.6252
Chandelier Exit (Short, 3 ATRs ) 30.0448
Upper Bollinger Band 33.5259
Lower Bollinger Band 27.6321
Percent B (%b) 0.04
BandWidth 19.274012
MACD Line 0.0136
MACD Signal Line 0.3512
MACD Histogram -0.3376
Fundamentals Value
Market Cap 1.78 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -14.74
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.15
Resistance 3 (R3) 31.47 30.68 30.60
Resistance 2 (R2) 30.68 29.84 30.53 30.42
Resistance 1 (R1) 29.27 29.32 28.88 28.95 30.23
Pivot Point 28.48 28.48 28.29 28.33 28.48
Support 1 (S1) 27.07 27.64 26.68 26.75 25.47
Support 2 (S2) 26.28 27.12 26.13 25.28
Support 3 (S3) 24.87 26.28 25.10
Support 4 (S4) 24.55